Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation

Kidney International

Volumn 71, Issue 11, 2007, Pages 1163-1171

  Singh, A K ^a   Coyne, D W ^b   Shapiro, W ^c   Rizkala, A R ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Brookdale Physicians Dialysis Center   (United States)

^d Watson Laboratories Inc   (United States)

Author keywords

Epoetin; Ferric gluconate; Ferritin; Response predictors; Reticulocyte hemoglobin content; Transferrin saturation

Indexed keywords

FERRIC GLUCONATE; FERRITIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE; THERAPY EFFECT; TRANSFERRIN BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AFRICAN AMERICANS; AGED; ANEMIA, IRON-DEFICIENCY; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FERRITINS; HEMATINICS; HEMATOCRIT; HEMOGLOBINS; HISPANIC AMERICANS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS; TRANSFERRIN; TREATMENT OUTCOME;

EID: 34249304479     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002223     Document Type: Article

References (24)

1. KDOQI Clinical Practice Guidelines and Clinical Practice. Recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47: S11-S145.
2. NKF-K/DOQI Clinical Practice. Guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37: S182-S238.
3. NKF-DOQI Clinical Practice. Guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997; 30: S192-S240.
4. Coyne DW. Iron indices: what do they really mean? Kidney Int 2006; 101: S4-S8.
5. Mittman N, Sreedhara R, Mushnick R et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 1997; 30: 912-922.
6. Tessitore N, Solero GP, Lippi G et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001; 16: 1416-1423.
7. Lin JL, Chang MY, Tan DT, Leu ML. Short-term small-dose intravenous iron trial to detect functional iron deficiency in dialysis patients. Am J Nephrol 2001; 21: 91-97.
8. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996; 7: 2654-2657.
9. Low CL, Bailie GR, Eisele G. Sensitivity and specificity of transferrin saturation and serum ferritin as markers of iron status after intravenous iron dextran in hemodialysis patients. Ren Fail 1997; 19: 781-788.
10. Coyne DW, Kapoian T, Suki W et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18: 975-984.
11. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. New Engl J Med 1999; 340: 448-454.
12. Aronoff GR. Safety of intravenous iron in clinical practice: implications for anemia management protocols. J Am Soc Nephrol 2004; 15: S99-S106.
13. Van Wyck DB, Bailie G, Aronoff G. Just the FAQs: frequently asked questions about iron and anemia in patients with chronic kidney disease. Am J Kidney Dis 2002; 39: 426-432.
14. Daschner M, Mehls O, Schaefer F. Soluble transferrin receptor is correlated with erythropoietin sensitivity in dialysis patients. Clin Nephrol 1999; 52: 246-252.
15. Ahluwalia N, Skikne BS, Savin V et al. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. Am J Kidney Dis 1997; 30: 532-541.
16. Fusaro M, Munaretto G, Spinello M et al. Soluble transferrin receptors and reticulocyte hemoglobin concentration in the assessment of iron deficiency in hemodialysis patients. J Nephrol 2005; 18: 72-79.
17. Chiang WC, Tsai TJ, Lin SL et al. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients. Clin Nephrol 2002; 58: 363-369.
18. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001; 60: 2406-2411.
19. Kaneko Y, Miyazaki S, Hirasawa Y et al. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. Kidney Int 2003; 63: 1086-1093.
20. Fishbane S, Galgano C, Langley Jr RC, Canfield W, Maesaka JK. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 1997; 52: 217-222.
21. Bhandari S, Brownjohn A, Turney J. Effective utilization of erythropoietin with intravenous iron therapy. J Clin Pharm Ther 1998; 23: 73-78.
22. Bovy C, Tsobo C, Capanzano L et al. Factors determining the percentage of hypochromic red blood cells in hemodialysis patients. Kidney Int 1999; 56: 1113-1119.
23. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 141-149.
24. Amgen Inc. Epogens® (epoetin alfa) Prescribing Information. 19-Dec-2006.